Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study

Publication Details

European Journal of Heart Failure

March 2026

Access Here

Author(s)

Yasuhiro Hamatani^{1 2}, Brian L Claggett¹, Muthiah Vaduganathan¹, Sarah Birkhoelzer³, Zi Michael Miao¹, Farooq H Sheikh⁴, Emre Aldinc⁵, Julian D Gillmore⁶, Marianna Fontana⁶, Scott D Solomon¹

Affiliations

¹Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA; ²National Hospital Organization Kyoto Medical Center, Kyoto, Japan; ³University Hospitals Dorset, Bournemouth, UK; ⁴MedStar Heart & Vascular Institute, Georgetown University School of Medicine, Washington, DC, USA; ⁵Alnylam Pharmaceuticals, Cambridge, MA, USA; ⁶National Amyloidosis Centre, Division of Medicine, UCL, Royal Free Hospital, London, UK

Abstract

Aims:

Vutrisiran was shown to maintain overall health status, as measured by the 23-item Kansas City Cardiomyopathy Questionnaire-overall summary score (KCCQ-OSS), in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in HELIOS-B. We assessed individual KCCQ components to better contextualize changes in KCCQ-OSS in a manner relevant to patients and clinicians.

Methods:

In this analysis of HELIOS-B, a double-blind, randomized, placebo-controlled trial of vutrisiran in ATTR-CM, we assessed treatment effect on mean score changes from baseline to 30 months for each 23 KCCQ components (scaled from 0 [worst] to 100 [best]) using a multivariable linear regression model. We further assessed overall changes in KCCQ-OSS as a function of age in both treatment groups to estimate the age-equivalent benefit observed.

Results:

Of 654 participants in HELIOS-B, 486 completed KCCQ assessment both at baseline and 30 months (age: 75 ± 6 years; 93% male; 91% wild-type ATTR; baseline KCCQ-OSS: 74.6 ± 18.9). Vutrisiran, compared with placebo, was associated with more favourable changes in most KCCQ components (median: +3.8, range: −0.9 to +7.6). The greater differences favouring vutrisiran were observed in ‘hurrying or jogging’, ‘walking on level ground,’ and ‘discouraged/down with heart failure’. Similar or greater benefits with vutrisiran were observed in patients not on tafamidis at baseline. KCCQ-OSS at 30 months was inversely related to age, with vutrisiran shifting the age-KCCQ-OSS relationship by approximately 11 years (95%CI: 3–20 years).

Conclusions:

In HELIOS-B, vutrisiran was associated with improvement in a wide range of individual KCCQ components, with the greatest benefits observed in physical limitations and quality-of-life domains.